US must meet tougher standard in Regeneron kickback lawsuit
Regeneron has won a court ruling that will make it harder for U.S. authorities to win a lawsuit accusing it of paying illegal ...
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...
Press Release: Dupixent Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...
Dupixent® (Dupilumab) Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 </stron ...